Skip to content

Advertisement

  • Oral presentation
  • Open Access

0314. Efficacy and safety of peginterferon alfa-2a + RBV in cHCV/HIV- vs cHCV-infected patients: interim analysis of a multicenter German cohort

  • 1,
  • 2,
  • 3,
  • 4,
  • 4,
  • 5 and
  • 6
Journal of the International AIDS Society201013 (Suppl 4) :O32

https://doi.org/10.1186/1758-2652-13-S4-O32

  • Published:

Keywords

  • Public Health
  • Infectious Disease
  • Detailed Analysis
  • Treatment Response
  • Preliminary Analysis

Purpose of the study

Eradicating cHCV is necessary for the subsequent management of patients with HIV and every HIV/HCV co-infected patient should be considered for treatment. We describe differences between cHCV mono-infected and cHCV/HIV co-infected patients in baseline factors and outcome of cHCV-treatment with peginterferon alfa 2a + RBV in the worldwide largest cHCV cohort.

Methods

Noninterventional prospective multicenter German cohort, started January 2008 and still recruiting. Interim analysis of cHCV patients, stratified for cHCV mono-infection and cHCV/HIV co-infection. The results are based on a cross-sectional analysis of all available data in April 2010.

Results

This interim analysis included 5.390 patients, who received HCV-treatment. 397 were cHCV/HIV co-infected (CI) and 4.993 cHCV mono-infected (MI). Main baseline- characteristics: 85.9% were GT1/4/5/6 patients in the CI-Group and 63.4% in the MI-Group, age was 41.0 (CI), 42.0 (MI) yrs, 89.7 (CI), 62.9 (MI)% were male, BMI was 22.8 (CI), 24.9 (MI) kg/m2, naïve/relapse/non-responder/re-infection: 86.4/3.8/4.5/5.3(CI), 88.0/6.1/5.3/0.6 (MI) %, source of infection (>1 answer possible): iv drug use 25.2(CI), 44.9(MI) %, sexual transmission 60.7 (CI), 4.1(MI)%, other 8.0 (CI), 24.0 (MI), unknown 13.1(CI), 33.0 (MI)%. 86.4 % of the co-infected patients received antiretroviral HIV-treatment (ART), 66.2 % of them had an HIV-RNA level below 50 copies/mL, median CD4-cells/µ count was 502. From those patients who finished treatment, 52.9% of the CI-Group and 67.7% of the MI-Group completed the planned course. Reasons for discontinuation (>1 answer possible) were non-response (59.3% in CI, 45.5 % in MI) and patient request (24.7% in CI, 14.5% in MI). Other reasons were tolerability (11.1% in CI, 12.0% in MI) and compliance issues (12.3% in CI, 10.5% in MI).Treatment response rates, stratified by genotypes, were already available regarding RVR and EVR (see Figure 1)

Figure 1

Conclusions

In this preliminary analysis HCV/HIV co-infected patients seemed to respond similar according to RVR and EVR in GT1/4/5/6 as HCV-mono infected patients on HCV-treatment. Treatment discontinuation due to non-response and patient request was much more common in the co-infected group. Other reasons for discontinuation like tolerability and compliance are equal in both arms.A more detailed analysis, in particular the influence of the HIV-ART on HCV-therapy outcome, may help interpreting these data. An updated analysis will be presented.

Authors’ Affiliations

(1)
Privat praxis Dupke/Carganico/Baumgarten, Berlin, Germany
(2)
Infektiologikum Frankfurt, Frankfurt, Germany
(3)
Praxis Koeppe/Kreckel, Berlin, Germany
(4)
Roche Pharma AG, Grenzach-Wyhlen, Germany
(5)
Center for HIV and Hepatogastroenterology, Düsseldorf, Germany
(6)
Universitätsklinikum Bonn, Medizinische Klinik Poliklinik 1, Bonn, Germany

Copyright

© Rockstroh et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement